Unilife Corporation
(ASX:UNS) has amended a clinical supply agreement with Novartis to allow an experimental drug trial.
Under an confidential deal for an exclusive agreement, Unilife will allow Novartis use of a customized delivery service that will enable Novartis to deliver an early-stage drug into a targeted organ in the body.
Unilife presently gets revenue from clinical product supplies but there are high hopes this novel drug will show success in a disease for which there are no current pharmacological treatments.
Unilife reported a net loss of $118.29 million for the 2015 financial year.
